Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03196349 · ClinicalTrials.gov registry record · Phase 4
Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism
A Phase 4 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
NCT03196349 is a Phase 4 study that was terminated before completion, run by Duke University. The registered enrollment target is 44 participants.
The verdict
NCT03196349, a Phase 4 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
Study Summary
Comparison of Oral anticoagulants (warfarin, apixaban and rivaroxaban) for extended VEnous Thromboembolism.
Interventions
- DRUG Warfarin
- DRUG Apixaban 2.5 MG
- DRUG Rivaroxaban 10 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2019-05-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03196349
The ClinicalTrials.gov registry entry for NCT03196349 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Warfarin is the first listed.
NCT03196349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03196349 about?
NCT03196349 is a clinical study titled "Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism". Comparison of Oral anticoagulants (warfarin, apixaban and rivaroxaban) for extended VEnous Thromboembolism.
What is the current status of trial NCT03196349?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2018-08-01. Estimated completion is 2019-05-01.
What interventions are being tested in trial NCT03196349?
The interventions under investigation include: Warfarin (DRUG), Apixaban 2.5 MG (DRUG), Rivaroxaban 10 MG (DRUG).
Who is sponsoring clinical trial NCT03196349?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.